Trial · NCT03350451
Adverse events216
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 216
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Feeling Cold | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 0 | 13 | |
| other | Feeling Cold | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Influenza Like Illness | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Influenza Like Illness | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 0 | 7 | |
| other | Injection Site Reaction | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 4 | 13 | |
| other | Injection Site Reaction | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 4 | 7 | |
| other | Non-cardiac Chest Pain | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 0 | 13 | |
| other | Non-cardiac Chest Pain | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Pain | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Pain | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 0 | 7 | |
| other | Pyrexia | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Pyrexia | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Vaccination Site Pain | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Vaccination Site Pain | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Vessel Puncture Site Haematoma | General disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Vessel Puncture Site Haematoma | General disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 0 | 7 | |
| other | Immunisation Reaction | Immune system disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Immunisation Reaction | Immune system disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Seasonal Allergy | Immune system disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Seasonal Allergy | Immune system disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 0 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03350451/events?page=3